Literature DB >> 12235

Interactions between viruses and bacteria in patients with chronic bronchitis.

C B Smith, C Golden, M R Klauber, R Kanner, A Renzetti.   

Abstract

The possibility that viral infections of the respiratory tract might predispose to bacterial colonization or infection was studied in 120 patients with chronic obstructive pulmonary disease and 30 control subjects; these individuals were observed for seven years. The ratio of the number of observed to the number of expected associations between viruses and bacteria was 2.43 (P = 0.037) for the pair influenza virus and Streptococcus pneumoniae and was 2.06 (P = 0.056) for influenza virus and Haemophilus influenzae. Consistently positive, but not significant, associations were detected between rhinovirus and herpes simplex virus infections and isolations of S. pneumoniae and H. influenzae. In contrast, isolations of the nonpathogenic Haemophilus parainfluenzae could not be related to prior viral infections. Significant rises in titer of antibody to H. influenzae were detected on 76 occasions, and 20 (26%) of these antibody rises were associated with viral or mycoplasmal infections during the preceding 120 days. The expected number of such associations was 8.34 (ratio of number observed to number expected, 2.40; P = 0.08). These results suggest that viral infections of the respiratory tract in patients with chronic obstructive pulmonary disease are associated with increased colonization by potentially pathogenic bacteria and may also predispose to infections with H. influenzae.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 12235      PMCID: PMC7109971          DOI: 10.1093/infdis/134.6.552

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  30 in total

Review 1.  Chronic airway disease: the infection connection.

Authors:  S B Greenberg; R L Atmar
Journal:  Trans Am Clin Climatol Assoc       Date:  1999

2.  Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent manner.

Authors:  Vasanthi Avadhanula; Carina A Rodriguez; John P Devincenzo; Yan Wang; Richard J Webby; Glen C Ulett; Elisabeth E Adderson
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 3.  COPD exacerbations . 2: aetiology.

Authors:  E Sapey; R A Stockley
Journal:  Thorax       Date:  2006-03       Impact factor: 9.139

4.  Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response.

Authors:  Timothy F Murphy; Aimee L Brauer; Brydon J B Grant; Sanjay Sethi
Journal:  Am J Respir Crit Care Med       Date:  2005-04-01       Impact factor: 21.405

5.  Identification of surface antigens of Moraxella catarrhalis as targets of human serum antibody responses in chronic obstructive pulmonary disease.

Authors:  Timothy F Murphy; Aimee L Brauer; Christoph Aebi; Sanjay Sethi
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

6.  Non-typeable Haemophilus influenzae protects human airway epithelial cells from a subsequent respiratory syncytial virus challenge.

Authors:  Stacey M Hartwig; Margaret Ketterer; Michael A Apicella; Steven M Varga
Journal:  Virology       Date:  2016-08-27       Impact factor: 3.616

7.  Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations.

Authors:  I S Patel; T A R Seemungal; M Wilks; S J Lloyd-Owen; G C Donaldson; J A Wedzicha
Journal:  Thorax       Date:  2002-09       Impact factor: 9.139

Review 8.  The impact of respiratory viral infections in patients with cystic fibrosis.

Authors:  C G Prober
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 9.  Impact of respiratory viral infections on cystic fibrosis.

Authors:  D Wat
Journal:  Postgrad Med J       Date:  2003-04       Impact factor: 2.401

Review 10.  Influenza infection and COPD.

Authors:  Patrick Mallia; Sebastian L Johnston
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.